Free Trial
→ I was right about SpaceX (From Brownstone Research) (Ad)tc pixel Free CLVR Stock Alerts

Clever Leaves (CLVR) Competitors

Clever Leaves logo
Compare

CLVR vs. CMRA, PXMD, CALA, EFTR, and SMFL

Should you be buying Clever Leaves stock or one of its competitors? The main competitors of Clever Leaves include Comera Life Sciences (CMRA), PaxMedica (PXMD), Calithera Biosciences (CALA), eFFECTOR Therapeutics (EFTR), and Smart for Life (SMFL). These companies are all part of the "pharmaceutical products" industry.

How does Clever Leaves compare to Comera Life Sciences?

Comera Life Sciences (NASDAQ:CMRA) and Clever Leaves (NASDAQ:CLVR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.

In the previous week, Comera Life Sciences' average media sentiment score of 0.00 equaled Clever Leaves'average media sentiment score.

Company Overall Sentiment
Comera Life Sciences Neutral
Clever Leaves Neutral

Comera Life Sciences has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500. Comparatively, Clever Leaves has a beta of 4212.86, meaning that its stock price is 421,186% more volatile than the S&P 500.

Clever Leaves has higher revenue and earnings than Comera Life Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Comera Life Sciences$1.00M0.00-$18M-$0.31N/A
Clever Leaves$17.42M0.00-$17.90M-$12.36N/A

Company Net Margins Return on Equity Return on Assets
Comera Life SciencesN/A N/A N/A
Clever Leaves N/A N/A N/A

6.9% of Clever Leaves shares are held by institutional investors. 8.9% of Comera Life Sciences shares are held by company insiders. Comparatively, 8.2% of Clever Leaves shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Clever Leaves beats Comera Life Sciences on 5 of the 7 factors compared between the two stocks.

How does Clever Leaves compare to PaxMedica?

PaxMedica (NASDAQ:PXMD) and Clever Leaves (NASDAQ:CLVR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.

Clever Leaves' return on equity of 0.00% beat PaxMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
PaxMedicaN/A -3,167.89% -560.35%
Clever Leaves N/A N/A N/A

In the previous week, PaxMedica's average media sentiment score of 0.00 equaled Clever Leaves'average media sentiment score.

Company Overall Sentiment
PaxMedica Neutral
Clever Leaves Neutral

4.9% of PaxMedica shares are held by institutional investors. Comparatively, 6.9% of Clever Leaves shares are held by institutional investors. 1.0% of PaxMedica shares are held by company insiders. Comparatively, 8.2% of Clever Leaves shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

PaxMedica has a beta of -0.99, meaning that its stock price is 199% less volatile than the S&P 500. Comparatively, Clever Leaves has a beta of 4212.86, meaning that its stock price is 421,186% more volatile than the S&P 500.

Clever Leaves has higher revenue and earnings than PaxMedica. PaxMedica is trading at a lower price-to-earnings ratio than Clever Leaves, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PaxMedicaN/AN/A-$18.29M-$6.09N/A
Clever Leaves$17.42M0.00-$17.90M-$12.36N/A

Summary

Clever Leaves beats PaxMedica on 8 of the 9 factors compared between the two stocks.

How does Clever Leaves compare to Calithera Biosciences?

Clever Leaves (NASDAQ:CLVR) and Calithera Biosciences (NASDAQ:CALA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Company Net Margins Return on Equity Return on Assets
Clever LeavesN/A N/A N/A
Calithera Biosciences N/A N/A N/A

In the previous week, Clever Leaves' average media sentiment score of 0.00 equaled Calithera Biosciences'average media sentiment score.

Company Overall Sentiment
Clever Leaves Neutral
Calithera Biosciences Neutral

6.9% of Clever Leaves shares are held by institutional investors. 8.2% of Clever Leaves shares are held by insiders. Comparatively, 6.6% of Calithera Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Clever Leaves has a beta of 4212.86, suggesting that its stock price is 421,186% more volatile than the S&P 500. Comparatively, Calithera Biosciences has a beta of -1.06, suggesting that its stock price is 206% less volatile than the S&P 500.

Clever Leaves has higher revenue and earnings than Calithera Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clever Leaves$17.42M0.00-$17.90M-$12.36N/A
Calithera BiosciencesN/AN/A-$39.65MN/AN/A

Summary

Clever Leaves beats Calithera Biosciences on 6 of the 6 factors compared between the two stocks.

How does Clever Leaves compare to eFFECTOR Therapeutics?

Clever Leaves (NASDAQ:CLVR) and eFFECTOR Therapeutics (NASDAQ:EFTR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

In the previous week, eFFECTOR Therapeutics had 1 more articles in the media than Clever Leaves. MarketBeat recorded 1 mentions for eFFECTOR Therapeutics and 0 mentions for Clever Leaves. Clever Leaves' average media sentiment score of 0.00 equaled eFFECTOR Therapeutics'average media sentiment score.

Company Overall Sentiment
Clever Leaves Neutral
eFFECTOR Therapeutics Neutral

Clever Leaves has higher revenue and earnings than eFFECTOR Therapeutics. eFFECTOR Therapeutics is trading at a lower price-to-earnings ratio than Clever Leaves, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clever Leaves$17.42M0.00-$17.90M-$12.36N/A
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A

6.9% of Clever Leaves shares are held by institutional investors. Comparatively, 57.7% of eFFECTOR Therapeutics shares are held by institutional investors. 8.2% of Clever Leaves shares are held by insiders. Comparatively, 4.7% of eFFECTOR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Clever Leaves has a beta of 4212.86, suggesting that its stock price is 421,186% more volatile than the S&P 500. Comparatively, eFFECTOR Therapeutics has a beta of 2.4, suggesting that its stock price is 140% more volatile than the S&P 500.

Company Net Margins Return on Equity Return on Assets
Clever LeavesN/A N/A N/A
eFFECTOR Therapeutics N/A N/A N/A

Summary

Clever Leaves beats eFFECTOR Therapeutics on 5 of the 8 factors compared between the two stocks.

How does Clever Leaves compare to Smart for Life?

Smart for Life (NASDAQ:SMFL) and Clever Leaves (NASDAQ:CLVR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations.

In the previous week, Smart for Life's average media sentiment score of 0.00 equaled Clever Leaves'average media sentiment score.

Company Overall Sentiment
Smart for Life Neutral
Clever Leaves Neutral

Clever Leaves has higher revenue and earnings than Smart for Life. Smart for Life is trading at a lower price-to-earnings ratio than Clever Leaves, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smart for Life$11.11M0.00-$22.68M-$14.48N/A
Clever Leaves$17.42M0.00-$17.90M-$12.36N/A

28.4% of Smart for Life shares are owned by institutional investors. Comparatively, 6.9% of Clever Leaves shares are owned by institutional investors. 31.7% of Smart for Life shares are owned by insiders. Comparatively, 8.2% of Clever Leaves shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Smart for Life has a beta of 16.53, meaning that its share price is 1,553% more volatile than the S&P 500. Comparatively, Clever Leaves has a beta of 4212.86, meaning that its share price is 421,186% more volatile than the S&P 500.

Company Net Margins Return on Equity Return on Assets
Smart for LifeN/A N/A N/A
Clever Leaves N/A N/A N/A

Summary

Clever Leaves beats Smart for Life on 4 of the 7 factors compared between the two stocks.

Get Clever Leaves News Delivered to You Automatically

Sign up to receive the latest news and ratings for CLVR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLVR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CLVR vs. The Competition

Export
MetricClever LeavesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1K$889.45M$6.25B$11.87B
Dividend YieldN/A4.84%2.73%5.21%
P/E Ratio0.001.7129.0428.48
Price / SalesN/A120.50476.4860.89
Price / CashN/A20.0727.6236.52
Price / BookN/A7.609.676.67
Net Income-$17.90M-$4.80M$3.55B$332.64M

Clever Leaves Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CLVR
Clever Leaves
N/AN/AN/AN/A$1K$17.42MN/A560
CMRA
Comera Life Sciences
N/AN/AN/AN/A$3K$1.00MN/A2
PXMD
PaxMedica
N/A$0.00
flat		N/AN/A$2KN/AN/A2
CALA
Calithera Biosciences
N/A$0.00
flat		N/AN/A$1KN/AN/A60
EFTR
eFFECTOR Therapeutics
N/A$0.00
flat		N/AN/A$1KN/AN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CLVR) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel